Swipe om te navigeren naar een ander artikel
It is important to understand the number, types and regions of trials that include patient-reported outcomes (PROs) to appreciate how patient experiences have been considered in studies of health and interventions. Twenty-seven percent of trials registered with ClinicalTrials.gov (2007–2013) included PROs; however, a regional breakdown was not provided and no reviews have been conducted of the Australia New Zealand Clinical Trials Registry (ANZCTR). We aimed to identify trials registered with ANZCTR with PRO endpoints and describe their characteristics.
ANZCTR was systematically searched from inception (2005) to 31 March 2017 for trials with PRO endpoints. Search terms included PRO measures listed in Patient-Reported Outcomes Quality of Life Instrument Database and Grid-Enabled Measures, as well as generic PRO terms (e.g. “quality of life” (QOL)). Trial endpoints were individually coded using an established framework to identify trials with PROs for the analysis.
Of 13,666 registered trials, 6168 (45.1%) included a PRO. The proportion of studies including PROs increased between 2006 and 2016 (r = 0.74, p = 0.009). Among the 6168 trials, there were 17,961 individual PRO endpoints, including symptoms/functional outcomes/condition-specific QOL (65.6%), generic QOL (13.2%), patient-reported experiences (9.9%), patient-reported behaviours (7.9%). Mental health was the most common category (99.8% included PROs), followed by physical medicine/rehabilitation (65.6%), musculoskeletal (63.5%), public health (63.1%), and cancer (54.2%).
Our findings suggest growing use of PROs in the assessment of health and interventions in ANZ. Our review identifies trial categories with limited patient-reported information and provides a basis for future work on the impact of PRO findings in clinical care.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Food and Drug Administration. (2009). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labelling claims. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf.
Chalmers, I., & Glasziou, P. (2009). Avoidable waste in the production and reporting of research evidence. The Lancet, 374(9683), 86–89. CrossRef
Glasziou, P., Altman, D. G., Bossuyt, P., Boutron, I., Clarke, M., Julious, S., et al. (2014). Reducing waste from incomplete or unusable reports of biomedical research. The Lancet, 383(9913), 267–276. CrossRef
Australian New Zealand Clinical Trials Registry. (2018). Statistics to the end of January 2018. http://www.anzctr.org.au/docs/Monthly%20Website%20Reporting_Statistics.pdf?t=139.
Vodicka, E., Kim, K., Devine, E. B., Gnanasakthy, A., Scoggins, J. F., & Patrick, D. L. (2015). Inclusion of patient-reported outcome measures in registered clinical trials: Evidence from ClinicalTrials.gov (2007–2013). Contemporary Clinical Trials, 43, 1–9. https://doi.org/10.1016/j.cct.2015.04.004. CrossRefPubMed
Australian New Zealand Clinical Trials Registry. ANZCTR data field explanation. 2017.
ePROVIDE., P. R. O. Q. O. L. I. D. (2018). https://www.eprovide.mapi-trust.org/about/about-proqolid#about_part_110356. Accessed 25 Jan 2018.
Grid-Enabled Measures Database. About GEM 2017 https://www.gem-beta.org/Public/About.aspx?cat=5. Accessed 25 Jan 2018.
European Medicines Agency. (2016). Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: The use of patient-reported outcome (PRO) measures in oncology studies. London: European Medicines Agency.
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., et al. (2015). A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 26(8), 1547–1573. CrossRefPubMed
Schnipper, L. E., Davidson, N. E., Wollins, D. S., Blayney, D. W., Dicker, A. P., Ganz, P. A., et al. (2016). Updating the American Society of Clinical Oncology value framework: Revisions and reflections in response to comments received. Journal of Clinical Oncology, 34(24), 2925–2934. CrossRefPubMed
- Trials with patient-reported outcomes registered on the Australian New Zealand Clinical Trials Registry (ANZCTR)
Chindhu Shunmuga Sundaram
the International Society for Quality of Life Research (ISOQOL)
- Springer International Publishing